Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine
Reference42 articles.
1. Gupta K, Yezdani M, Sotelo T, Aragon-Ching JB (2015) A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 24:1059–1073
2. Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J (2017) A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate 77:1213–1220
3. Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia, past, present and future. Differentiation 82:184–199
4. Schauer IG, Rowley DR (2011) The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82:200–210
5. Li F, Pascal LE, Zhou J, Zhou Y, Wang K, Parwani AV, Dhir R, Guo P (2018) BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and / or celecoxib. Ncbi.Nlm.Nih.Gov (6):1–10
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献